Mandate

Vinge advises in conjunction with the sale of Astrego Diagnostics to Sysmex

May 02, 2022 M&A

Vinge has advised the main owners of Astrego Diagnostics AB in conjunction with the sale of the shares to the Japanese minority owner, Sysmex Corporation.

Astrego has developed a diagnostic tool for determining the presence of bacteria in patient samples and the determination of resistance against different antibiotics (so-called ”Antibiotic Susceptibility Test, AST”).

Vinge’s team consisted of Johan WinnerbladEléonore FribergViktoria Owetz Leyva and Gunilla Nyman.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024